4a69f90c20fbac1822c314e026bae912 *DESCRIPTION
c798c12d80812fea27d0b6b2c2e92b8c *LICENSE
dc21c19f0d6968ee25d441b2cf46017d *NAMESPACE
56d36d885dd3fc339d91acb04744e004 *NEWS.md
07892fc73e7268422f3cb10e65b6f68d *R/data-jab.adverse.reactions.R
1b3b0fa64e7e5a51847b32897a7ee07f *R/jab.adverse.reactions.R
3873180695734c615a6a755eb641ae98 *README.md
92a12b0c5eba530363ced20900d5e24a *data/jab_adverse_reactions.RData
f2698804da16497de0f6d60571f006ac *inst/data-raw/jab.adverse.reactions.create.R
3df1de3bcb2015191b8b7d674ed74315 *inst/pdf/5.3.6-postmarketing-experience.pdf
0d9e1ae5a951579d2b1e751550ec477d *inst/pdf/Neuritis_and_Multiple_Neuritis_Following_Serum_Therapy.pdf
32ddac7f3ab7d7c42e27e40413051fbd *inst/pdf/VRBPAC-10.22.20-Presentation-COVID19-CBER-Monitoring-Vaccine.pdf
6e5247ae3b9790ac941a55492a7a3896 *inst/public/jab_adverse_reactions.csv
4fdf756b59eda8586ff12b7385d3b9ee *inst/public/jab_adverse_reactions.json
336324cebfabea2e647d371ef662cb79 *inst/public/jab_adverse_reactions.xml
bfac90fb03f48b2d7c215916cc182566 *inst/references/Data_References.bib
8223ca187bb02e642beccb2b85b036ec *man/jab.adverse.reactions.Rd
cddc0e89b4f010a2732a347e0b2db87a *man/jab_adverse_reactions.Rd
